Modeling long-term PM2.5 exposure and its impact on premature coronary artery disease: A pooled analyses of multiple cohorts in India
Project Description
Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation. Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.
Project Duration
2023 - 2026
Project Lead
Dr Santu Ghosh
Authors
Dr Santu Ghosh
Project Status
completed
Project Type
Health Effects Institute, Boston, USA